The patient with a heart murmur: Evaluation, assessment and dental considerations

Journal of the American Dental Association

Volumn 136, Issue 3, 2005, Pages 347-356

  Lessard, Eric ^a   Glick, Michael ^b   Ahmed, Sultan ^b   Saric, Muhamed ^b  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Dentistry; Echocardiography; Heart murmur

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; DEXFENFLURAMINE; DIGITALIS; ERYTHROMYCIN; FENFLURAMINE; FLUCONAZOLE; KETOCONAZOLE; LOCAL ANESTHETIC AGENT; METRONIDAZOLE; NITROUS OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PENICILLIN G; PHENTERMINE; TETRACYCLIC ANTIDEPRESSANT AGENT; TETRACYCLINE; WARFARIN;

ANTIBIOTIC PROPHYLAXIS; AORTA STENOSIS; AORTA VALVE; AORTA VALVE REGURGITATION; AUSCULTATION; BACTERIAL ENDOCARDITIS; BREAST CANCER; CANCER RADIOTHERAPY; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CONGENITAL HEART DISEASE; CONGESTIVE CARDIOMYOPATHY; DENTIST; DENTISTRY; DIET; ECHOCARDIOGRAPHY; EHLERS DANLOS SYNDROME; ESOPHAGUS CANCER; FALLOT TETRALOGY; HEALTH CARE PERSONNEL; HEART ATRIOVENTRICULAR VALVE; HEART ATRIUM FIBRILLATION; HEART ATRIUM SEPTUM DEFECT; HEART MURMUR; HEART PALPITATION; HEART SOUND; HEART VALVE PROSTHESIS; HEMOSTASIS; HODGKIN DISEASE; HUMAN; LOCAL ANESTHESIA; LUNG CANCER; MARFAN SYNDROME; MITRAL VALVE; MITRAL VALVE PROLAPSE; MITRAL VALVE REGURGITATION; NONHODGKIN LYMPHOMA; OSTEOGENESIS IMPERFECTA; PATENT DUCTUS ARTERIOSUS; PATIENT CARE; PHARYNGITIS; PRACTICE GUIDELINE; PULMONARY VALVE; REVIEW; RHEUMATIC HEART DISEASE; RISK FACTOR; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; STICKLER SYNDROME; STREPTOCOCCUS GROUP A; SYNCOPE; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX PAIN; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRICUSPID VALVE; TRISOMY 21; VALVULAR HEART DISEASE; WEIGHT REDUCTION; DENTAL CARE; ECHOGRAPHY; UTILIZATION REVIEW;

ANTIBIOTIC PROPHYLAXIS; DENTAL CARE FOR CHRONICALLY ILL; ECHOCARDIOGRAPHY; ENDOCARDITIS, BACTERIAL; HEART MURMURS; HUMANS;

EID: 84860929880     PISSN: 00028177     EISSN: None     Source Type: Journal    
DOI: 10.14219/jada.archive.2005.0176     Document Type: Article

References (43)

1. Braunwald E. Heart disease: A textbook of cardiovascular medicine. 6th ed. Philadelphia: Saunders; 2001:63.
2. Bickley LS, Hoekelman RA, Bates B. Bate's guide to physical examination and history taking. 7th ed. Philadelphia: Lippincott; 1999:277-332.
3. Marino B, Vairo U, Corno A, et al. Atrioventricular canal in Down syndrome: prevalence of associated cardiac malformations compared with patients without Down syndrome. Am J Dis Child 1990;144:1120-2.
4. O'Connell AC, Marini JC. Evaluation of oral problems in an osteogenesis imperfecta population. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999;87(2):189-96.
5. De Coster PJ, Martens LC, De Paepe A. Oral manifestation of patients with Marfan syndrome: a case-control study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;93:564-72.
6. Webb AC, Markus AF. The diagnosis and consequences of Stickler syndrome. Br J Oral Maxillofac Surg 2002;40(1):49-51.
7. Dajani AS, Taubert KA, Wilson W, et al. Prevention of bacterial endocarditis: recommendations by the American Heart Association. JAMA 1997;277:1794-801.
8. Brickner ME, Hillis LD. Lange RA. Congenital heart disease in adults: second of two parts. N Engl J Med 2000;342:334-42.
9. Bonow RO, Carabello B. de Leon AC, et al. ACC/AHA guidelines for the management of patients with valvular heart disease. Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). J Heart Valve Dis 1998;7:672-707.
10. Shipton B, Wahba H. Valvular heart disease: review and update. Am Fam Physician 2001;63:2201-8.
11. Miller CS, Egan RM, Falace DA, Rayens MK, Moore CR. Prevalence of infective endocarditis in patients with systemic lupus erythematosus. JADA 1999;130:387-92.
12. Barasch A, Safford MM. Diet medications and valvular heart disease: the current evidence. Spec Care Dentist 2002;22(3):108-14.
13. Saric M, Kronzon I. Aortic stenosis in the elderly. Am J Geriatr Cardiol 2000;9:321-9, 345.
14. Bouknight DP, O'Rourke RA. Current management of mitral valve prolapse. Am Fam Physician 2000;61:3343-50, 53-4.
15. Lavie CJ. Echocardiography for mitral valve prolapse? Postgrad Med 1999;105(1):34, 37.
16. Moder KG, Miller TD, Tazelaar HD. Cardiac involvement in systemic lupus erythematosus. Mayo Clin Proc 1999;74:275-84.
17. Cheitlin MD, Alpert JS, Armstrong WF, et al. ACC/AHA Guidelines for the clinical application of echocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Developed in collaboration with the American Society of Echocardiography. Circulation 1997;95:1686-744.
18. Jensen-Urstad K, Svenungsson E, de Faire U, et al. Cardiac abnormalities are frequent in systemic lupus erythematosus patients with manifest arterial disease. Lupus 2002;11:744-52.
19. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine [published correction appears in N Engl J Med 1997;337:1783]. N Engl J Med 1997;337:581-8.
20. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997. MMWR Morb Mortal Wkly Rep 1997;46:1061-6.
21. Jollis JG, Landolfo CK, Kisslo J, Constantine GD, Davis KD, Ryan T. Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. Circulation 2000;101:2071-7.
22. Weissman NJ, Tighe JF Jr, Gottdiener JS, Gwynne JT. Prevalence of valvular-regurgitation associated with dexfenfluramine three to five months after discontinuation of treatment. J Am Coll Cardiol 1999;34:2088-95.
23. Adams MJ, Hardenbergh PH, Constine LS, Lipshultz SE. Radiation-associated cardiovascular disease. Crit Rev Oncol Hematol 2003;45(1):55-75.
24. Heidenreich PA, Hancock SL, Lee BK, Mariscal CS, Schnittger I. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol 2003;42:743-9.
25. Colao A, Spinelli L, Marzullo P, et al. High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. J Clin Endocrinol Metab 2003;88:3196-201.
26. Attenhofer Jost CH, Turina J, Mayer K, et al. Echocardiography in the evaluation of systolic murmurs of unknown cause. Am J Med 2000;108:614-20.
27. Roldan CA, Shively BK, Crawford MH. Value of cardiovascular physical examination for detecting valvular heart disease in asymptomatic subjects. Am J Cardiol 1996;77:1327-31.
28. Bloch A, Crittin J, Jaussi A. Should functional cardiac murmurs be diagnosed by auscultation or by echocardiography? Clin Cardiol 2001;24:767-9.
29. Gaskin PR, Owens SE, Talner NS, Sanders SP, Li JS. Clinical auscultation skills in pediatric residents. Pediatrics 2000;105:1184-7.
30. Murtagh B, Frazier OH, Letsou GV. Diagnosis and management of bacterial endocarditis in 2003. Curr Opin Cardiol 2003;18(2):106-10.
31. San Roman JA, Vilacosta I, Zamorano JL, Almeria C, Sanchez-Harguindey L. Transesophageal echocardiography in right-sided endocarditis. J Am Coll Cardiol 1993;21:1226-30.
32. Kuruppu JC, Corretti M, Mackowiac P, Roghmann MC. Overuse of transthoracic echocardiography in the diagnosis of native valve endocarditis. Arch Intern Med 2002;162:1715-20.
33. Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000;30:633-8.
34. Singh JP, Evans JC, Levy D, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol 1999;83:897-902. Erratum in: Am J Cardiol 1999;84:1143.
35. Randall CW, Kressin NR, Garcia RI, et al. Heart murmurs: are older male dental patients aware of their existence? JADA 2001;132(2):171-6.
36. Freeman RV, Otto CM. Management of asymptomatic valvular aortic stenosis. Indian Heart J 2002;54(1):31-8.
37. Cecil RL, Goldman L, Bennett JC. Cecil textbook of medicine. 21st ed. Philadelphia: Saunders; 2000:160-378.
38. Glick M, Siegel MA, Brightman VJ. Evaluation of the dental patient: diagnosis and medical risk assessment. In: Burket LW, Greenberg MS, Glick M, eds. Burket's oral medicine. 10th ed. Hamilton, Ontario: B.C. Decker; 2003:27.
39. Fuster V, Ryden LE, Asinger RW, American College of Cardiology/American Heart Association/European Society of Cardiology Board, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001;38:1231-66.
40. Tyler MT, Lozada-Nur F, Glick M, eds. Clinician's guide to treatment of medically compromised dental patients. 2nd ed. Baltimore: American Academy of Oral Medicine; 2001:4.
41. Hallonsten AL, Koch G, Schroder U. Nitrous oxide-oxygen sedation in dental care. Community Dent Oral Epidemiol 1983;11:347-55.
42. Bader JD, Bonito AJ, Shugars DA. A systematic review of cardiovascular effects of epinephrine on hypertensive dental patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;93:647-53.
43. Glick M. Screening for traditional risk factors for cardiovascular disease: a review for oral health care providers. JADA 2002;133:291-300.